Tetrodotoxin for Moderate to Severe Cancer-Related Pain: A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Parallel-Design Trial

Objective. This study evaluated subcutaneous injections of tetrodotoxin (TTX) for the treatment of moderate to severe, inadequately controlled cancer-related pain. Methods. Eligible patients were randomized to receive TTX (30 μg) or placebo subcutaneously twice daily for four consecutive days. Effic...

Full description

Saved in:
Bibliographic Details
Main Authors: Neil A. Hagen, Lyne Cantin, John Constant, Tina Haller, Gilbert Blaise, May Ong-Lam, Patrick du Souich, Walter Korz, Bernard Lapointe
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:Pain Research and Management
Online Access:http://dx.doi.org/10.1155/2017/7212713
Tags: Add Tag
No Tags, Be the first to tag this record!